Shareholders of Zhejiang Shengda Bio-Pharm, Wanjian Investment, plan to reduce their shareholding by no more than 3%; multiple shareholders of Montage Technology plan to collectively reduce their shareholding by no more than 2%; South Chip Technology has cumulatively reduced its shareholding by 1% in Shanghai; shareholders of Kangxi Communication, Yancheng Semiconductors and Gongqingcheng Kangsheng, plan to reduce their shareholding by no more than 3%; Jiangsu Zhongshe Group has terminated its plan for a significant asset restructuring; First Tractor has terminated its significant asset sale; Kexing Biopharm has terminated the clinical trial of its interferon α2b spray.
